The glycosylation of the influenza A virus hemagglutinin by mammalian cells - A site-specific study

被引:85
|
作者
MirShekari, SY
Ashford, DA
Harvey, DJ
Dwek, RA
Schulze, IT
机构
[1] ST LOUIS UNIV,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,ST LOUIS,MO 63104
[2] UNIV OXFORD,DEPT BIOCHEM,GLYCOBIOL INST,OXFORD OX1 3QU,ENGLAND
关键词
D O I
10.1074/jbc.272.7.4027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have characterized the glycans at individual sites on the hemagglutinin of three influenza A variants to obtain information on the role of cell-specific glycosylation in determining the receptor binding properties of this virus, The variants differ in whether they have a glycosylation site at residue 129 on the tip of the hemagglutinin and whether amino acid 184 (near to the receptor binding site) is His or Asn. We found that all sites on each variant are glycosylated in Madin-Darby bovine kidney cells, that the glycosylation is site-specific, and that the glycans at the same site in each variant are highly similar. One site that is buried in the hemagglutinin trimer contains only oligomannose glycans, The remaining sites carry complex glycans of increasing size as the distance of the site from the viral membrane decreases, Most of these complex glycans are terminated with alpha-galactose residues, a consequence in bovine cells of the removal of terminal sialic acids by the viral neuraminidase, Although the glycans at residue 129 are among the smallest on the molecule, they are large enough to reach the receptor binding pocket on their own and adjacent monomers. The results suggest that the reduction in receptor binding observed with Madin-Darby bovine kidney cell-grown virus is due to the combined effect of large complex glycans at the tip of the hemagglutinin and a His to Asn substitution close to the receptor binding pocket.
引用
收藏
页码:4027 / 4036
页数:10
相关论文
共 50 条
  • [1] SITE-SPECIFIC GLYCOSYLATION OF THE INFLUENZA-VIRUS HEMAGGLUTININ
    MIRSHEKARI, SY
    ASHFORD, DA
    SCHULZE, IT
    GLYCOCONJUGATE JOURNAL, 1993, 10 (04) : 277 - 277
  • [2] Characterization of Site-Specific Glycosylation in Influenza A Virus Hemagglutinin Produced by Spodoptera frugiperda Insect Cell Line
    Liu, Yan-Jun
    Wu, Shiaw-Lin
    Love, Kerry R.
    Hancock, William S.
    ANALYTICAL CHEMISTRY, 2017, 89 (20) : 11036 - 11043
  • [3] SITE-SPECIFIC MUTAGENESIS OF THE FUSION PEPTIDE OF INFLUENZA-VIRUS HEMAGGLUTININ
    GETHING, MJ
    DOMS, RW
    WHITE, J
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 49 - 49
  • [4] Glycosylation of Influenza A Virus Hemagglutinin
    Schwarzer, J.
    Rapp, E.
    Reichl, U.
    CELLS AND CULTURE, 2010, 4 : 621 - 623
  • [5] Measuring Site-specific Glycosylation Similarity between Influenza a Virus Variants with Statistical Certainty
    Chang, Deborah
    Hackett, William E.
    Zhong, Lei
    Wan, Xiu-Feng
    Zaia, Joseph
    MOLECULAR & CELLULAR PROTEOMICS, 2020, 19 (09) : 1533 - 1545
  • [6] Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin
    Stray, Stephen J.
    Pittman, Lindsey B.
    VIROLOGY JOURNAL, 2012, 9
  • [7] STUDIES ON THE MECHANISM OF MEMBRANE-FUSION - SITE-SPECIFIC MUTAGENESIS OF THE HEMAGGLUTININ OF INFLUENZA-VIRUS
    GETHING, MJ
    DOMS, RW
    YORK, D
    WHITE, J
    JOURNAL OF CELL BIOLOGY, 1986, 102 (01): : 11 - 23
  • [8] Subtype- and antigenic site-specific differences in biophysical influences on evolution of influenza virus hemagglutinin
    Stephen J Stray
    Lindsey B Pittman
    Virology Journal, 9
  • [9] Variation of Site-Specific Glycosylation Profiles of Recombinant Influenza Glycoproteins
    Goecker, Zachary C.
    Burke, Meghan C.
    Remoroza, Concepcion A.
    Liu, Yi
    Mirokhin, Yuri A.
    Sheetlin, Sergey L.
    Tchekhovskoi, Dmitrii, V
    Yang, Xiaoyu
    Stein, Stephen E.
    MOLECULAR & CELLULAR PROTEOMICS, 2024, 23 (09)
  • [10] Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry
    Cruz, Esteban
    Cain, Joel
    Crossett, Ben
    Kayser, Veysel
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (03) : 508 - 517